Share

March 2017; 4 (2) ArticleOpen Access

An observational study of alemtuzumab following fingolimod for multiple sclerosis

Mark Willis, Owen Pearson, Zsolt Illes, Tobias Sejbaek, Christian Nielsen, Martin Duddy, Kate Petheram, Caspar van Munster, Joep Killestein, Clas Malmeström, Emma Tallantyre, Neil Robertson
First published January 10, 2017, DOI: https://doi.org/10.1212/NXI.0000000000000320
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
2385

Share

Article Information

vol. 4 no. 2 e320
DOI: 
https://doi.org/10.1212/NXI.0000000000000320
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received October 5, 2016
  • Accepted in final form December 5, 2016
  • First Published January 10, 2017.
Copyright & Usage: 
Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology This is an open access article distributed under the terms of the Creative Commons Attribution License 4.0 (CC BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Author Disclosures

    1. Mark Willis, BSc, MBBCh, MRCP,
    2. Owen Pearson, MBBCh, MD, FRCP,
    3. Zsolt Illes, MD, PhD,
    4. Tobias Sejbaek, MD,
    5. Christian Nielsen, MSc, PhD,
    6. Martin Duddy, MD, FRCP,
    7. Kate Petheram, BSc, MBChB, MRCP,
    8. Caspar van Munster, MD, PhD,
    9. Joep Killestein, MD, PhD,
    10. Clas Malmeström, MD, PhD,
    11. Emma Tallantyre, PhD, MRCP and
    12. Neil Robertson, MD, FRCP
  1. Mark Willis, BSc, MBBCh, MRCP,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) Wellcome Trust Research Training Fellowship

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Owen Pearson, MBBCh, MD, FRCP,
    3. Scientific Advisory Boards:

    1. (1)Biogen, Novartis, Roche (2)UK MS register

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Biogen, Roche, Merck Serono, Novartis, Teva, Genzyme Sanofi.

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Zsolt Illes, MD, PhD,
    4. Scientific Advisory Boards:

    1. (1) Biogen Idec (2) Novartis (3) Sanofi-Aventis-Genzyme (4) Teva Pharmaceuticals

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Biogen Idec (2) Novartis (3) Sanofi-Aventis-Genzyme (4) Teva Pharmaceuticals (5) Bayer Healthcare (5) Merck Serono

    Editorial Boards:

    1. Clinical and Experimental Neuroimmunology

    Patents:

    1. Lambertsen K, Clausen B, Nielsen HH, Finsen B, Illes Z. 2015. Fumaric acid derivates for Medical use. No. PCT/DK2015/050344. The use of fumaric acid derivates in acute ischemic stroke.

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Biogen Idec

    Research Support, Government Entities:

    1. (1)Region of Southern Denmark, primary investigator, 2014

    Research Support, Academic Entities:

    1. (1)Odense University Hospital

    Research Support, Foundations and Societies:

    1. (1)Scleroseforeningen (2) Lundbeckfonden (3) Direktor Ejnar Jonasson, kaldet Johnsen, og Hustru's Mindelegat

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Tobias Sejbaek, MD,
    5. Scientific Advisory Boards:

    1. Novartis, Biogen, Teva, Merck, Roche

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Biogen, Teva, Novartis

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Christian Nielsen, MSc, PhD,
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Martin Duddy, MD, FRCP,
    7. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Sanofi Genzyme, speaker honoraria, travel to conference, advisory board (2) Novartis, speaker honoraria, travel to conference, advisory board (3) Biogen, speaker honoraria, travel to conference, advisory board (4) Merck, speaker honoraria (5) Teva, speaker honoraria, travel to conference (6) Roche, honorarium for development of educational programme, advisory board (7) Medscape, development and delivery of online educational programme

    Editorial Boards:

    1. Multiple Sclerosis Journal, Associate Editor, 2013-present

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Novartis (2) Biogen (3) Roche (4) Sanofi Genzyme

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) MS Trust, London, UK

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. Kate Petheram, BSc, MBChB, MRCP,
    8. Scientific Advisory Boards:

    1. (1) Roche Product Limited. Scientific advisory board.

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Genzyme Sanofi. Funding for travel and speaker honoraria. (2) Biogen Idec. Funding for travel.

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  8. Caspar van Munster, MD, PhD,
    9. Scientific Advisory Boards:

    1. (1) Commercial, compensation for serving in a scientific advisory board from Merck Serono.

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Commercial, honoraria for lecturing and consulting from Novartis Pharma AG (2) Commercial, honoraria for lecturing and consulting from Biogen-Idec (3) Commercial, honoraria for lecturing and consulting from Merck Serono

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  9. Joep Killestein, MD, PhD,
    10. Scientific Advisory Boards:

    1. Consultancy (advisory boards) Novartis, Merck-Serono, Biogen, Genzyme, TEVA, Roche

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Speaker honoraria Biogen, Novartis, TEVA, Merck-Serono, Roche

    Editorial Boards:

    1. Editor of the official scientific journal of the Dutch Society of Neurology, the Dutch Society of Neurosurgeons and the Society of Flemish Neurologists (Tijdschrift voor Neurologie en Neurochirurgie). Editorial board MS Journal

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Consultancy Novartis, Merck-Serono, Biogen Idec, Genzyme, TEVA

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. I have been involved in clinical trials of companies that market drugs for MS (Schering AG, Biogen Idec, Merck-Serono, Teva, Genzyme, Novartis and Roche).

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  10. Clas Malmeström, MD, PhD,
    11. Scientific Advisory Boards:

    1. (1)Biogen-Idec, Merck-Serono, Novartis and Roche

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Biogen-Idec, Merck-Serono, Novartis and Roche

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  11. Emma Tallantyre, PhD, MRCP and
    12. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. I received salary from Biogen Idec as part of a fellowship scheme.

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  12. Neil Robertson, MD, FRCP
    13. Scientific Advisory Boards:

    1. Professor Robertson has served on Advisory boards for Genzyme, Roche, Novartis, Biogen

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Professor Robertson has recieved honoraria for speaking at academic meetings from Biogen and Genzyme

    Editorial Boards:

    1. Professor robertson serves as an editor for the Journal of Neurology since 2012

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Neuroimmunology Fellowship Genzyme Mortality of MS Novartis

    Research Support, Government Entities:

    1. National institute of Heath Wales, co-applicant 2015-18

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Multiple Sclerosis society of Great Britain and Northern Ireland Welcome Trust

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Neurology (M.W., E.T., N.R.), Institute of Psychological Medicine and Clinical Neuroscience, Cardiff University, University Hospital of Wales; Department of Neurology (O.P.), Morriston Hospital, Heol Maes Eglwys, Morriston, Swansea, UK; Departments of Neurology (Z.I., T.S.) and Clinical Immunology (C.N.), Odense University Hospital, University of Southern Denmark; Department of Neurology (M.D.), The Royal Victoria Infirmary, Newcastle upon Tyne; Department of Neurology (K.P.), Sunderland Royal Hospital, UK; VU University Medical Center (C.v.M., J.K.), Amsterdam, the Netherlands; and Department of Neurology (C.M.), Sahlgrenska Academy at the University of Gothenburg, Institute of Clinical Neuroscience and Physiology, Gothenburg, Sweden.
  1. Correspondence to Dr. Robertson: RobertsonNP{at}cardiff.ac.uk
View Full Text

Article usage

Article usage: January 2017 to April 2023

AbstractFullPdfSource
Jan 2017362506128Highwire
Jan 2017014760pmc
Feb 20173228549Highwire
Feb 20170374171pmc
Mar 201739720099Highwire
Mar 2017015559pmc
Apr 20172509568Highwire
Apr 20174177122pmc
May 20171123025Highwire
May 201745355396pmc
Jun 2017731226Highwire
Jun 20173589111pmc
Jul 201774829Highwire
Jul 2017254357pmc
Aug 2017571312Highwire
Aug 2017163744pmc
Sep 2017351211Highwire
Sep 2017194863pmc
Oct 201754714Highwire
Oct 2017265461pmc
Nov 2017402411Highwire
Nov 2017355154pmc
Dec 201715113Highwire
Jan 201803631Highwire
Feb 20184199Highwire
Mar 201821911Highwire
Apr 201823311Highwire
Apr 2018144045pmc
May 201804712Highwire
Jun 20180325Highwire
Jun 201892937pmc
Jul 20180258Highwire
Aug 20185153Highwire
Aug 2018103246pmc
Sep 20183207Highwire
Oct 20180466Highwire
Nov 20187425Highwire
Dec 20180335Highwire
Jan 20190419Highwire
Feb 201964811Highwire
Mar 201922012Highwire
Apr 20192188Highwire
May 20196249Highwire
Jun 20192198Highwire
Jul 201933113Highwire
Aug 20192168Highwire
Sep 20198327Highwire
Oct 20190316Highwire
Nov 201913414Highwire
Dec 201911615Highwire
Jan 20201254Highwire
Feb 20202317Highwire
Mar 20202189Highwire
Apr 20201105Highwire
May 20201236Highwire
Jun 20202216Highwire
Jul 20202164Highwire
Aug 20202157Highwire
Sep 20203279Highwire
Oct 202013311Highwire
Nov 20205185Highwire
Dec 20208226Highwire
Jan 20214174Highwire
Feb 202152912Highwire
Mar 202122116Highwire
Apr 20213159Highwire
May 20213226Highwire
Jun 20214211Highwire
Jul 20213447Highwire
Aug 202134510Highwire
Sep 20213468Highwire
Oct 2021330022Highwire
Nov 2021419332Highwire
Dec 202113964Highwire
Jan 202202126Highwire
Feb 202232175Highwire
Mar 202212326Highwire
Apr 202212434Highwire
May 202232199Highwire
Jun 202242687Highwire
Jul 202211785Highwire
Aug 202262005Highwire
Sep 2022426113Highwire
Oct 2022525311Highwire
Nov 20221624225Highwire
Dec 202242504Highwire
Jan 2023424711Highwire
Feb 202392095Highwire
Mar 202371497Highwire
Apr 20232838Highwire

Cited By...

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me

Recommended articles